Overview of JAK Inhibitor Inhaled Formulation

Time: 11:15 am
day: Day One


  • Cataloguing autoimmune diseases where JAK inhalation may be sensible
  • Considering toxicity and potential for off-target effects with inhaled JAKs
  • Evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of
    a novel potent pan-JAK inhaled as a dry powder